The CTN Pilot Study Program will duplicate all ofthe proven methods previously used in Phases I and II to determine which investigators are most likely to become independently funded following CTN support.
The aims of this program are:
Specific Aim 1 : Facilitating the generation of preliminary data for submission of novel grant applications by early stage and established investigators. While early stage investigators are targeted for selective development, some awards may be used to support particularly novel research by established individuals, as long as cutting-edge scientific criteria are met. The applications, as was the case for the first set of pilot studies selected (see below), will be reviewed and scored independently by the EAC.
Specific Aim 2 : Develop novel treatments and improved outcomes for neurological disorders. Given the translational mission ofthe CTN, we are interested in advancing the field of novel therapeutic interventions and improving outcomes, especially of underserved populations, and will target upgrading or expansion of Core Facilities to further this aim.
Specific Aim 3 : Implement the strategic plan (see Overview) to secure awards clustered around the missions of selected NIH institutes, e.g. NICHD, NINDS, in order to facilitate future P30 support. In order to develop a competitive application for future P30 support, a major requirement by most institutes is the required inclusion of a number of awards, usually at least five from the same institute that will be served by the P30. We have considerable strength in NICHD funding and may soon have a critical mass of awards in order to be competitive for a P30 award from that institute. However, we plan to guide our research by targeting another institute in whose area we some strengths, NINDS. The selection ofthe Pilot Study awards has already been undertaken by the EAC and these projects center on movement disorders. Given a few new awards, we should be competitive for support for a P30 from NINDS as well. The long-term plan, therefore, is to begin gathering the critical mass of awards for at least two P30 applications during the next 3-4 years.
Specific Aim 4 : Carry out a Program Evaluation of four major portions ofthe CTN, the Mentoring Plan, Leadership Program, Pilot Study Program, and Core Utilization. Data collection forms, interviews, meeting minutes, website database, conference evaluation forms, and satisfaction surveys will be used to evaluate program implementation and outcomes. Responses to evaluations will be drafted for the progress reports to the EAC and lAC. This process will optimize the effectiveness of each of the major elementis of the CTN, with the long-term goals of providing sufficient and convincing information, a) on substantive deviations from the outlined objectives, expected activities, time frames, or outcomes so that corrective actions promptly implemented, and b) facilitating the adoption ofthe program on an institution-wide basis.
These aims will cement a foundation for a self-sustaining and successful center that can compete successfully for P30 support.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Center Core Grants (P30)
Project #
1P30GM110702-01
Application #
8751020
Study Section
Special Emphasis Panel (ZGM1-TWD-C (3C))
Project Start
Project End
Budget Start
2014-06-10
Budget End
2015-04-30
Support Year
1
Fiscal Year
2014
Total Cost
$430,694
Indirect Cost
$141,637
Name
University of Arkansas for Medical Sciences
Department
Type
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Fantegrossi, William E; Gray, Bradley W; Bailey, Jessica M et al. (2015) Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT?A receptors, in mice. Psychopharmacology (Berl) 232:1039-47
Mulkey, Sarah B; Swearingen, Christopher J (2014) Advancing neurologic care in the neonatal intensive care unit with a neonatal neurologist. J Child Neurol 29:31-5
Penthala, Narsimha R; Bommagani, Shobanbabu; Janganati, Venumadhav et al. (2014) Heck products of parthenolide and melampomagnolide-B as anticancer modulators that modify cell cycle progression. Eur J Med Chem 85:517-25
Smith, Douglas A; Bailey, Jessica M; Williams, Diarria et al. (2014) Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. J Pharmacol Exp Ther 351:485-91
Lairamore, Chad I; Garrison, Mark K; Bourgeon, Laetitia et al. (2014) Effects of functional electrical stimulation on gait recovery post-neurological injury during inpatient rehabilitation. Percept Mot Skills 119:591-608
Hyde, James; MacNicol, Melanie; Odle, Angela et al. (2014) The use of three-dimensional printing to produce in vitro slice chambers. J Neurosci Methods 238:82-7
Ziu, Endrit; Hadden, Coedy; Li, Yicong et al. (2014) Effect of serotonin on platelet function in cocaine exposed blood. Sci Rep 4:5945
Hall, Richard W; Anand, Kanwaljeet J S (2014) Pain management in newborns. Clin Perinatol 41:895-924
Yates, Charlotte C; Mitchell, Anita J; Booth, Melissa Y et al. (2014) The effects of massage therapy to induce sleep in infants born preterm. Pediatr Phys Ther 26:405-10